Rhythm Pharmaceuticals' quarterly revenue climbed from $29.1M in Q2 2024 to $92.1M in Q3 2026, with year-over-year growth of 79.6% in the latest quarter and gross margins holding between 86.8% and 91.6%, which suggests strong commercial traction and orphan-drug pricing power.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue scaled to $92.1M in Q3 2026 with gross margins near 87% and a narrowing operating loss of -$39.3M, though operating margin of -42.6% remains deeply negative.
Rhythm Pharmaceuticals is dedicated to transforming patient lives by advancing precision medicines for rare neuroendocrine diseases, addressing root causes.
The company operates globally, rapidly developing treatments that could significantly impact underserved patient populations with rare conditions.
Rhythm Pharmaceuticals receives attention from analysts, with stock forecasts and price target predictions indicating potential growth and investor interest.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 3, 2026 | -$0.61+14.0% vs -$0.71 | $92M+7.7% vs $86M |
Q3 2026 Aug 4, 2026 | -$0.73+9.6% vs -$0.81 | $71M+5.3% vs $68M |
Q2 2026 May 5, 2026 | -$0.83+3.5% vs -$0.86 | $60M+7.8% vs $56M |
Q1 2026 Feb 26, 2026 | -$0.73+7.6% vs -$0.79 | $57M+1.9% vs $56M |
AstraZeneca recently made a roughly $10 billion offer to buy Rhythm Pharmaceuticals, according to people familiar with the matter, a deal that would expand its portfolio of rare disease treatments.
-- Expanded guidance based on additional evidence demonstrating the benefits of IMCIVREE in adults living with Bardet-Biedl syndrome -- BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the National Institute for Health and Care Excellence (NICE) has issued a positive guidance for IMCIVREE® (setmelanotide) to include adults living with genetically confirmed Bardet-Biedl syndrome (BBS).
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2026 Earnings Call Transcript
Rhythm Pharmaceuticals NASDAQ: RYTM reported third-quarter global net product sales of $92.1 million, up 29% sequentially, as the company cited a strong early U.S. launch for IMCIVREE in acquired hypothalamic obesity, or acquired HO. The company also outlined plans to advance bivamelagon into Phase III studies for acquired HO and Prader-Willi syndrome, while expanding its international commercial footprint.
Benchmark RYTM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Rhythm Pharmaceuticals, Inc. (RYTM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $112.28 | $7.7B | -40.00 | 45.83% | -69.03% | -83.68% | — | |
| $103.63 | $12.29B | 26.18 | 37.55% | 26.93% | 544.26% | — | |
| $15.43 | $1.52B | -3.01 | 20.13% | -71.78% | — | — | |
| $44.61 | $2.86B | 28.34 | 15.24% | 10.2% | 5.22% | 0.25% | |
| $65.44 | $5.43B | -51.55 | 114.51% | -9.17% | — | — | |
| $300.88 | $8.87B | 41.21 | 33.94% | 47.91% | 17.02% | — |
Rhythm Pharmaceuticals, Inc. (RYTM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Rhythm Pharmaceuticals, Inc. (RYTM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 3, 2026·SEC
Aug 4, 2026·SEC
Jun 25, 2026·SEC
Get notified when RYTM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Rhythm Pharmaceuticals, Inc. (RYTM) stock FAQ — growth, dividends, profitability & financials explained
Rhythm Pharmaceuticals, Inc. (RYTM) reported $280.7M in revenue over the trailing twelve months. Revenue was $189.8M in fiscal year 2025.
Rhythm Pharmaceuticals, Inc. (RYTM) grew revenue by 61.0% over the trailing twelve months, compared with the twelve months before.
No. Rhythm Pharmaceuticals, Inc. (RYTM) reported a net loss of $193.8M over the trailing twelve months.
Rhythm Pharmaceuticals, Inc. (RYTM) had a return on equity (ROE) of -83.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
Rhythm Pharmaceuticals, Inc. (RYTM) had negative free cash flow of $127.4M over the trailing twelve months.
